The Minister’s address was particularly notable for the announcement of a planned rollout of lenacapavir, a biannual ...

The Global Fund has secured access to lenacapavir, a groundbreaking HIV prevention drug, for low and middle-income countries, ...

South Africa's government has estimated that universities and science councils could lose about $107 million in U.S. research funding over the next five years due to the aid cuts, which affect not ...

There is widespread hope for curbing HIV after the United States Food and Drug Administration (FDA) approved an injectable ...

Gilead announced a deal to get its groundbreaking HIV prevention drug to lower income countries. Notably, the deal does not ...

Lenacapavir offers twice-yearly HIV prevention with near-complete protection in clinical trials. Clinical trials show ...

A twice-yearly injection could help Australia eliminate HIV, but experts are sounding the alarm over its prohibitive cost.

The FDA has approved a breakthrough preventative treatment for HIV that could change the course of the AIDS epidemic. But ...

Gilead will supply lenacapavir to Global Fund countries for HIV prevention, but questions remain amid PEPFAR cuts and funding ...

Gilead Sciences (GILD) stock in focus as the company joins The Global Fund to expand access to lenacapavir, an HIV PrEP ...

Gilead Sciences and the Global Fund to Fight AIDS, Tuberculosis and Malaria said on Wednesday they had finalized plans to supply a long-acting HIV prevention drug to low-income countries, despite the ...

Lower-income countries will gain access to a "game-changing" HIV prevention drug with a new deal signed between US ...